ATE69725T1 - Pharmazeutische zubereitungen von acrivastine. - Google Patents

Pharmazeutische zubereitungen von acrivastine.

Info

Publication number
ATE69725T1
ATE69725T1 AT88302658T AT88302658T ATE69725T1 AT E69725 T1 ATE69725 T1 AT E69725T1 AT 88302658 T AT88302658 T AT 88302658T AT 88302658 T AT88302658 T AT 88302658T AT E69725 T1 ATE69725 T1 AT E69725T1
Authority
AT
Austria
Prior art keywords
acrivastine
pharmaceutical preparations
formulations
copolymer
acrylic
Prior art date
Application number
AT88302658T
Other languages
English (en)
Inventor
Harry Phillip Jones
Robert Judson Mackey
Michael John Desmond Gamlen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE69725T1 publication Critical patent/ATE69725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT88302658T 1987-03-27 1988-03-25 Pharmazeutische zubereitungen von acrivastine. ATE69725T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878707416A GB8707416D0 (en) 1987-03-27 1987-03-27 Pharmaceutical formulations
EP88302658A EP0284408B1 (de) 1987-03-27 1988-03-25 Pharmazeutische Zubereitungen von Acrivastine

Publications (1)

Publication Number Publication Date
ATE69725T1 true ATE69725T1 (de) 1991-12-15

Family

ID=10614818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88302658T ATE69725T1 (de) 1987-03-27 1988-03-25 Pharmazeutische zubereitungen von acrivastine.

Country Status (21)

Country Link
US (2) US4954350A (de)
EP (1) EP0284408B1 (de)
JP (1) JP2753297B2 (de)
KR (1) KR960006067B1 (de)
AT (1) ATE69725T1 (de)
AU (1) AU606149B2 (de)
CA (1) CA1303504C (de)
DE (1) DE3866390D1 (de)
DK (1) DK175660B1 (de)
ES (1) ES2027005T3 (de)
FI (1) FI92904C (de)
GB (1) GB8707416D0 (de)
GR (1) GR3003224T3 (de)
HU (1) HU202102B (de)
IE (1) IE61166B1 (de)
IL (1) IL85872A (de)
NO (1) NO175618C (de)
NZ (1) NZ224024A (de)
PT (1) PT87082B (de)
WO (1) WO1988007369A1 (de)
ZA (1) ZA882167B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5188836A (en) * 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5514655A (en) * 1993-05-28 1996-05-07 Abbott Laboratories Enteral nutritional with protein system containing soy protein hydrolysate and intact protein
US6103262A (en) * 1994-01-27 2000-08-15 G. D. Searle & Company Modified-release metronidazole compositions and methods for making and using same
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU7501398A (en) * 1997-05-21 1998-12-11 Warner-Lambert Company Non-sedating acrivastine preparation
ES2263211T3 (es) 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
JP2000128776A (ja) * 1998-10-19 2000-05-09 Asahi Chem Ind Co Ltd フィルムコーティング顆粒およびその製造方法
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
WO2002034268A1 (en) * 2000-10-23 2002-05-02 Ono Pharmaceutical Co., Ltd. Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
AR040684A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion solida recubierta y metodo de preparacion de la misma
EP1981487B1 (de) * 2006-02-07 2014-06-25 Fmc Corporation Latex oder pseudolatex beschichtungszusammensetzungen und beschichtungsverfahren
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
JP5283623B2 (ja) * 2007-07-17 2013-09-04 旭化成ケミカルズ株式会社 水系組成物
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
PL2677878T3 (pl) * 2011-02-23 2016-08-31 Intercontinental Great Brands Llc Wstępna mieszanka substancji smakowych dla gumy do żucia, sposoby otrzymywania wstępnej mieszanki substancji smakowych oraz kompozycji gumy do żucia
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3170764D1 (en) * 1980-11-12 1985-07-04 Ciba Geigy Ag Fast disaggregating pharmaceutical tablet
EP0052075A1 (de) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Körnige Arzneimittel-Retardform
US4562258A (en) * 1982-02-04 1985-12-31 Findlay John W A 6-[3-Amino-1-(4-tolyl)prop-1E-enyl]pyridine-2-carboxylic acid derivatives having antihistaminic activity
YU44821B (en) * 1982-02-04 1991-02-28 Wellcome Found Process for obtaiing new pyridyl derivatives
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
LU85058A1 (fr) * 1983-10-24 1985-06-19 Pharlyse Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB2159715B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition in sustained release unit dose form and process for its preparation
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
EP0212745B1 (de) * 1985-08-16 1991-04-10 The Procter & Gamble Company Partikel mit konstanter Wirkstofffreisetzung
JPS6261916A (ja) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
EP0265061B1 (de) * 1986-09-18 1992-01-08 London School of Pharmacy Innovations Ltd Arzneiformulierung
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Also Published As

Publication number Publication date
NO885123L (no) 1988-11-16
PT87082A (pt) 1988-04-01
NO175618C (no) 1994-11-09
NZ224024A (en) 1990-06-26
EP0284408A1 (de) 1988-09-28
DK662688D0 (da) 1988-11-25
HUT50627A (en) 1990-03-28
FI885460L (fi) 1988-11-24
WO1988007369A1 (en) 1988-10-06
NO885123D0 (no) 1988-11-16
AU606149B2 (en) 1991-01-31
AU1496788A (en) 1988-11-02
GB8707416D0 (en) 1987-04-29
ZA882167B (en) 1989-11-29
IE61166B1 (en) 1994-10-05
FI885460A0 (fi) 1988-11-24
JP2753297B2 (ja) 1998-05-18
DE3866390D1 (de) 1992-01-09
ES2027005T3 (es) 1992-05-16
FI92904C (fi) 1995-01-25
IE880901L (en) 1988-09-27
CA1303504C (en) 1992-06-16
DK175660B1 (da) 2005-01-10
US5370880A (en) 1994-12-06
PT87082B (pt) 1992-07-31
IL85872A0 (en) 1988-09-30
JPH01502754A (ja) 1989-09-21
FI92904B (fi) 1994-10-14
EP0284408B1 (de) 1991-11-27
US4954350A (en) 1990-09-04
NO175618B (de) 1994-08-01
KR960006067B1 (ko) 1996-05-08
IL85872A (en) 1992-03-29
GR3003224T3 (en) 1993-02-17
DK662688A (da) 1988-11-25
HU202102B (en) 1991-02-28
KR890700344A (ko) 1989-04-24

Similar Documents

Publication Publication Date Title
ATE69725T1 (de) Pharmazeutische zubereitungen von acrivastine.
HUT56267A (en) Process for producing pharmaceutical compositions having controlled release of active ingredient
KR880010759A (ko) 방출 조절성 제제
ES2080796T3 (es) Formulaciones de productos farmaceuticos de liberacion prolongada.
MA21182A1 (fr) Ester 2,3,5,6-tetrafluorobenzylique d'acide (+) 1r-trans-2,2-dimeghyl-3-(2,2 dichlorovinyl) -cyclopropane-carboxylique, son procede de preparation et composition insecticide le contenant.
DE69212879D1 (de) Magensaftstabile pharmazeutische Formulierungen zur Oral Verbreichung von Gallensäuren
SE8602722L (sv) Hallbara administreringsformer
SE8803822D0 (sv) Novel dosage form
DE3856258D1 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
NO883261D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
DE3887068D1 (de) 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ATE4411T1 (de) Prostaglandin-verbindungen enthaltende pharmazeutische praeparate und verfahren zu deren herstellung.
IL85776A (en) Pharmaceutical compositions comprising certain selenium containing algae and c18-c22 unsaturated acids and their preparation,used for treating conditions of the heart and cardiovascular system
DE3685275D1 (de) Herstellung von 5-fluor-2'-deoxyuridin estern zur intravenoesen verabreichung.
NO911892D0 (no) Fremgangsmaate for fremstilling og anvendelse som medikamenter av alfa-oksopyrrol(2,3-b)indoleddiksyrer, estere, amider og beslektede analoger.
DE3889259D1 (de) Trapidil enthaltende pharmazeutische Zusammensetzungen und Verfahren zu ihrer Herstellung.
AT342761B (de) Verfahren zur herstellung von homopyrimidazol-derivate enthaltenden, stabilen pharmazeutischen praparaten zur oralen verabreichung
AR002736A1 (es) Uso de ester 3-metil-5-etilico de acido 2,6-dimetil-4-(2,3-diclorofenil-1,4 -dihidropiridin-3,5-dicarboxilico (felodipina) para fabricar un medicamento ypreparacion farmaceutica para el tratamiento de la disfuncion cerebral.
DE68928788D1 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
TH4604B (th) สูตรผสมในทางเภสัชกรรมของแอไครแวสทีน
ATE53993T1 (de) 1,4-dihydropyridincarbonsaeure-ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE94883T1 (de) Salze von glykosaminoglykanen, verfahren zu ihrer herstellung und diese salze enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time